1. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature. 2001. 409:860–921.

2. Venter JC, Adams MD, Meyers EW, et al. The sequence of the human genome. Science. 2001. 291:1304–1351.

3. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev. 1999. 20:649–688.

4. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes. 1998. 47:507–514.

5. Auwerx J. PPARgamma, the ultimate thrifty gene. Diabetologia. 1999. 42:1033–1049.

6. Beamer BA, Negri C, Yen CJ, Gavrilova O, Rumberger JM, Durcan MJ, Yarnall DP, Hawkins AL, Griffin CA, Burns DK, Roth J, Reitman M, Shuldiner AR. Chromosomal localization and partial genomic structure of the human peroxisome proliferator activated receptor-gamma (hPPAR gamma) gene. Biochem Biophys Res Commun. 1997. 233:756–759.

7. Stumvoll M, Häring H. The peroxisome proliferator-activated receptor-γ2 Pro12Ala polymorphism. Diabetes. 2002. 51:2341–2347.

8. Vigouroux C, Fajas L, Khallouf E, Meier M, Gyapay G, Lascols O, Auwerx J, Weissenbach J, Capeau J, Magre J. Human peroxisome proliferatoractivated receptor-gamma2: genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes. Diabetes. 1998. 47:490–492.

9. Mori H, Ikegami H, Kawaguchi Y, Seino S, Yokoi N, Takeda J, Inoue I, Seino Y, Yasuda K, Hanafusa T, Yamagata K, Awata T, Kadowaki T, Hara K, Yamada N, Gotoda T, Iwasaki N, Iwamoto Y, Sanke T, Nanjo K, Oka Y, Matsutani A, Maeda E, Kasuga M. The Pro12→Ala substitution in PPAR-γ is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes. 2001. 50:891–894.

10. Tönjes A, Stumvoll M. The role of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor γ in diabetes risk. Curr Opin Clin Nutr Metab Care. 2007. 10:410–414.

11. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J. A Pro12Ala substitution in PPARg2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998. 20:284–287.

12. Masugi J, Tamori Y, Mori H, Koike T, Kasuga M. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferatoractivated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun. 2000. 268:178–182.

13. Ridker PM, Cook NR, Cheng S, Erlich HA, Lindpaintner K, Plutzky J, Zee RY. Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol. 2003. 23:859–863.

14. Herrmann SM, Ringel J, Wang JG, Staessen JA, Brand E. Peroxisome proliferator-activated receptor-γ2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes. Diabetes. 2002. 51:2653–2657.

15. Caramori ML, Canari LH, Costa LA, Gross JL. The human Peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. Diabetes. 2003. 52:3010–3013.

16. Pollex RL, Mamakeesick M, Zinman B, Harris SB, Hegele RA, Hanley AJG. Peroxisome proliferator-activated receptor g polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes. J Diabetes Complicat. 2007. 21:166–171.

17. Jorsal A, Tarnow L, Lajer M, Ek J, Hansen T, Pedersen O, Parving HH. The PPAR gamma 2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy. Mol Genet Metab. 2008. 94:347–351.

18. Lee KH, Jeong HS, Choi KY, Kim H, Lee DS, Kang JY, Jeon HJ, Oh TK. Association Study of the Peroxisome Proliferators-Activated Receptor γ2 Pro12Ala Polymorphism with Diabetic Nephropathy. Korean Diabetes J. 2008. 32:402–408.